Clinical Trials for Cervical Cancer

Study of Intratumoral Injections of VLPONC-01 in Head and Neck Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with head and neck squamous cell carcinoma eligible for intratumoral injection: either unresectable/recurrent/metastatic disease post–PD-1/PD-L1 and standard therapies (IT VLPONC-01 alone) or resectable stage I–IVb disease planned for surgery (neoadjuvant pembrolizumab with or without IT VLPONC-01). VLPONC-01 is a virus replicon particle–delivered self-amplifying RNA encoding IL-12 to drive local innate/adaptive immune activation and potentially sensitize tumors to PD-1 blockade.

ClinicalTrials.gov ID: NCT06736379

Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/metastatic HNSCC who have progressed on or were intolerant to prior PD‑1–based therapy receive single‑agent cetuximab (weekly IV), an anti‑EGFR monoclonal antibody that blocks ligand-induced signaling and mediates ADCC. Single-arm study assessing response rate, with secondary PFS/OS and safety.

ClinicalTrials.gov ID: NCT04375384

3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with incurable head and neck squamous cell carcinoma (including prior RT/systemic therapy and allowing metastatic disease) are randomized to short-course SBRT in 3–5 fractions versus conventional palliative external-beam radiation. The trial compares symptom relief and local control while monitoring toxicity.

ClinicalTrials.gov ID: NCT05674396

Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated metastatic NSCLC (squamous or nonsquamous without targetable drivers) or incurable recurrent/metastatic HNSCC eligible for pembrolizumab-based first line receive an alternating induction schedule of chemoimmunotherapy cycles interspersed with pembrolizumab monotherapy. Regimens use standard backbones (carboplatin/paclitaxel or nab-paclitaxel for squamous NSCLC; carboplatin/pemetrexed with optional pemetrexed maintenance for nonsquamous NSCLC; carboplatin/5-FU for HNSCC) plus pembrolizumab, an anti–PD-1 antibody.

ClinicalTrials.gov ID: NCT05358548

A Prospective Cohort Study of Integrating Radiotherapy Into Chemotherapy With Pembrolizumab and Bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with newly diagnosed, untreated stage IVB, PD-L1–positive cervical cancer (squamous/adenocarcinoma/adenosquamous), ECOG 0–1, receive induction cisplatin/paclitaxel plus pembrolizumab (anti–PD-1) and bevacizumab (anti-VEGF), followed by definitive pelvic EBRT with brachytherapy while continuing pembrolizumab/bevacizumab. Designed to assess safety and efficacy of adding definitive radiotherapy to the current chemoimmunotherapy/bevacizumab backbone; excludes prior systemic therapy/RT or checkpoint inhibitors and active autoimmune disease.

ClinicalTrials.gov ID: NCT06543576

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/metastatic salivary gland cancers enroll into two cohorts: adenoid cystic carcinoma with recent progression, or non-ACC (SDC, intermediate/high-grade adenocarcinoma NOS, MEC) after ≤3 prior palliative chemotherapies (HER2+ must have received HER2 therapy), ECOG 0–1. Treatment is sacituzumab govitecan, a Trop-2–targeted antibody–drug conjugate delivering SN-38, given IV on days 1 and 8 of 21-day cycles; safety and efficacy are assessed separately by histology.

ClinicalTrials.gov ID: NCT05884320

An Open-Label Phase II Clinical Trial Assessing the Safety, Feasibility, Efficacy and Immunological Correlates of Heterologous Prime-Boost With pBI-11 (IM) and TA-HPV (IM) Combined With Pembrolizumab as Treatment for Patients With Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/metastatic, p16+/hrHPV+ oropharyngeal carcinoma and PD-L1 CPS≥1 eligible for first-line pembrolizumab receive a heterologous HPV vaccine prime-boost (pBI-11 DNA vaccine encoding HPV16/18 antigens and TA-HPV recombinant vaccinia expressing HPV16/18 E6/E7) plus pembrolizumab. Aims to enhance HPV-specific cellular immunity and improve response versus PD-1 blockade alone; excludes prior systemic therapy for R/M disease and patients with active CNS metastases or significant immunosuppression/autoimmunity.

ClinicalTrials.gov ID: NCT05799144

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with iodine‑avid but RAI‑insufficient papillary/follicular DTC with unresectable locoregional invasion and/or distant metastases receive individualized combination therapy of systemic I‑131 and external beam radiotherapy, using integrated dosimetry to escalate cumulative dose (target ≥80 Gy) to selected lesions. Aims to assess safety and preliminary efficacy with coordinated RAI+XRT planning in patients with adequate organ function and no contraindications to TSH stimulation or radiation.

ClinicalTrials.gov ID: NCT04892303

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic androgen receptor–positive salivary gland carcinoma (ECOG 0–1), including previously treated patients without prior ADT or checkpoint inhibitors, receive goserelin (GnRH agonist ADT) plus pembrolizumab (anti–PD-1) until progression or toxicity. Stable, treated brain metastases are allowed; key exclusions include active autoimmune disease requiring systemic therapy and significant immunosuppression.

ClinicalTrials.gov ID: NCT03942653

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic HNSCC (oropharynx, oral cavity, hypopharynx, or larynx) receive subcutaneous amivantamab—an EGFR/MET bispecific antibody—either as monotherapy or combined with pembrolizumab, paclitaxel, or pembrolizumab plus carboplatin, with cohort-specific HPV/p16 requirements and prior therapy allowances. The study assesses safety and antitumor activity across these regimens and establishes the recommended dose for the amivantamab-paclitaxel combination.

ClinicalTrials.gov ID: NCT06385080